Zinc and Selenium supplementation in patients with CKDu.
Phase 4
Not yet recruiting
- Conditions
- Chronic kidney disease of uncertain etiology in Sri Lanka.
- Registration Number
- SLCTR/2019/001
- Lead Sponsor
- Department of Medicine, Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
• Age 18-60 years
• Able to provide informed consent and willing to complete the follow-up visit
• Estimated glomerular filtration rate between 30 and 60 ml/min/1.73m2
• Suffering from CKDu (ie other identifiable causes of CKD excluded)
Exclusion Criteria
• History of allergy to Zinc or Selenium
• Hemodialysis or peritoneal dialysis currently or within six months of recruitment
• Renal transplant recipient
• Pregnancy
• Breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link selenium and zinc supplementation to CKDu progression in Sri Lanka?
How does selenium-zinc supplementation compare to standard care in CKDu patient outcomes?
Which biomarkers correlate with response to selenium and zinc in CKDu management?
What adverse events are associated with selenium and zinc supplementation in CKDu patients?
Are there combination therapies involving selenium and zinc for CKDu that show improved efficacy?